Atlas Trials

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

Clinical trial NCT05925504 · RECRUITING

Trial details

NCT number
NCT05925504
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lower Risk MDS Per IPSS-R
Start date
2023-07-01
Primary completion
2026-06-30
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.